Lamotrigine in the treatment of bipolar disorder

Charles L. Bowden, Nancy U. Karren

Research output: Contribution to journalArticle

42 Scopus citations

Abstract

Lamotrigine has undergone a remarkable series of systematic studies since 1994 that now establish it as an efficacious, well-tolerated treatment in bipolar disorder. Its efficacy principally addresses both acute and maintenance phase benefits on depressive symptomatology. These benefits have been demonstrated in placebo-controlled studies, rapid cycling patients, bipolar I and II patients and monotherapy as well as in combination therapy, although this has been less well studied. The drug is exceptionally well-tolerated in long-term treatment, although initial dosing requires gradual dosage escalation to avoid the risk of inducing serious rashes with features within the spectrum of Stevens-Johnson syndrome. Administration with valproate requires a slower dosage titration, whereas, as with many drugs, administration with carbamazepine requires a more rapid dosage increase. In contrast to marketed antidepressants, lamotrigine appears not to induce manic or hypomanic episodes, nor to increase cycling frequency. This combination of properties makes it a first-choice treatment for acute bipolar depression and continuation treatment, especially, but not limited to, prophylaxis against recurrent depression and depressive symptoms. Lamotrigine appears not to have acute antimanic properties. A small number of studies suggest a broader spectrum of efficacy, including in some axis I disorders that are comorbidly associated with bipolar disorder.

Original languageEnglish (US)
Pages (from-to)1513-1519
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Volume3
Issue number10
DOIs
Publication statusPublished - Oct 1 2002

    Fingerprint

Keywords

  • Bipolar
  • Depression
  • Lamotrigine
  • Manic-depressive
  • Treatment

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this